Alzamend Neuro Presents Preliminary AL001 Brain Connectivity Findings
Alzamend Neuro presented preliminary fMRI findings comparing AL001 with lithium carbonate in six healthy participants. The study showed descriptive differences in brain connectivity, but no changes survived statistical correction. The company noted the small sample size and need for further study. The findings were presented at the Society for Neuroscience annual meeting on November 18, 2026, according to an SEC filing.
How this was made

The 30-second read
Why it matters
Because the results are exploratory and do not survive FDR correction, the disclosure is more supportive of continued research than of a definitive efficacy signal.
Market read
Traders may treat this as an early biomarker update, but the lack of statistically robust connectivity changes likely limits immediate re-rating catalysts.
What to watch
The article does not state effect sizes, imaging endpoints beyond connectivity, or whether the study was powered for these analyses, limiting interpretation of biological relevance.
Background
The company presented preliminary resting-state fMRI connectivity findings for AL001 compared with lithium carbonate in healthy participants at the Society for Neuroscience annual meeting.
Ticker impact
Alzamend Neuro (AL001) presented preliminary resting-state fMRI connectivity results versus lithium carbonate, with no connectivity changes surviving FDR correction.
Likely limited near-term upside as the data are explicitly preliminary and fail multiple-testing correction, reducing conviction.
The article emphasizes small n=6, exploratory findings, and that no network-pair connectivity changes survived false discovery rate correction.
Market effects
Adds incremental clinical-development signal for neuroimaging biomarkers in CNS drug development, but without confirmatory statistics.
None indicated.
None indicated.
Counterpoint
Exploratory connectivity differences could still motivate protocol refinement or larger-cohort studies, which may be viewed positively by some biotech traders despite lack of FDR significance.
Key entities
- companyAlzamend Neuro, Inc.
Issuer presenting preliminary AL001 brain connectivity findings versus lithium carbonate.
- drug_candidateAL001
Investigational candidate evaluated in the resting-state fMRI study.
- comparatorLithium carbonate
Standard-of-care comparator used in the study design.
